Works in Investigational New Drugs, 2022, Vol 40, Issue 3

Results: 24

The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 556, doi. 10.1007/s10637-022-01238-2

By:

Nicolai, Alice;
Taurone, Samanta;
Carradori, Simone;
Artico, Marco;
Greco, Antonio;
Costi, Roberta;
Scarpa, Susanna

Publication type:

Article

Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 622, doi. 10.1007/s10637-022-01235-5

By:

Powell, Steven F.;
Mazurczak, Miroslaw;
Dib, Elie G.;
Bleeker, Jonathon S.;
Geeraerts, Louis H.;
Tinguely, Matthew;
Lohr, Michele M.;
McGraw, Steven C.;
Jensen, Ashley W.;
Ellison, Christie A.;
Black, Lora J.;
Puumala, Susan E.;
Reed, Valerie J.;
Miskimins, W. Keith;
Lee, John H.;
Spanos, William C.

Publication type:

Article

Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 565, doi. 10.1007/s10637-022-01233-7

By:

Márquez, Marcela;
Olausson, Karl Holmberg;
Alaiya, Ayodele;
Nilsson, Sten;
Meurling, Lennart;
Holmberg, Anders R.

Publication type:

Article

Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 546, doi. 10.1007/s10637-022-01231-9

By:

Xue, Ting;
Xu, Peijia;
Padelford, Jonathan;
Xue, Xingkui;
Wu, Alyssa Y.;
Li, Yuancheng;
Wang, Liya

Publication type:

Article

Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.

Published in:

2022

By:

Waqar, Saiama N.;
Robinson, Clifford;
Olszanski, Anthony J.;
Spira, Alexander;
Hackmaster, Melissa;
Lucas, Luisa;
Sponton, Laura;
Jin, Hulin;
Hering, Ursula;
Cronier, Damien;
Grinberg, Marianna;
Seithel-Keuth, Annick;
Diaz-Padilla, Ivan;
Berlin, Jordan

Publication type:

Correction Notice

The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 668, doi. 10.1007/s10637-022-01225-7

By:

Kokkali, Stefania;
Kotsantis, Ioannis;
Magou, Elpida;
Sophia, Talagani;
Kormas, Theodoros;
Diakoumis, Giakoumis;
Spathas, Nikolaos;
Psyrri, Amanda;
Ardavanis, Alexandros

Publication type:

Article

IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 537, doi. 10.1007/s10637-022-01224-8

By:

Huo, Jia;
Fu, Lijun;
Jin, Mengyuan;
Li, Zhaoming;
Zhang, Mingzhi

Publication type:

Article

An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 614, doi. 10.1007/s10637-022-01223-9

By:

Mizukami, Takuro;
Minashi, Keiko;
Hara, Hiroki;
Nishina, Tomohiro;
Amanuma, Yusuke;
Takahashi, Naoki;
Nakasya, Akio;
Takahashi, Masaki;
Nakajima, Takako Eguchi

Publication type:

Article

The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 529, doi. 10.1007/s10637-022-01222-w

By:

Kang, Chang-Won;
Hannan, Katherine M.;
Blackburn, Anneke C.;
Loh, Amos H. P.;
Hong, Kuick Chik;
Yuan, Goh Jian;
Hein, Nadine;
Drygin, Denis;
Hannan, Ross D.;
Coupland, Lucy A.

Publication type:

Article

A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 606, doi. 10.1007/s10637-022-01220-y

By:

Ding, Fangfang;
Huang, Jie;
Feng, Zeying;
Kuang, Yun;
Yang, Shuang;
Xiang, Yuxia;
Zou, Chan;
Yang, Guoping

Publication type:

Article

Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 650, doi. 10.1007/s10637-022-01219-5

By:

Wu, Jing-Jing;
Wang, Wen-Hua;
Dong, Meng;
Ma, Shan-Shan;
Zhang, Xu-Dong;
Zhu, Li-Nan;
Niu, Song-Tao;
Ding, Meng-Jie;
Zhang, Jie-Ming;
Zhang, Lei;
Li, Xin;
Li, Ling;
Sun, Zhen-Chang;
Wang, Xin-Hua;
Fu, Xiao-Rui;
Li, Zhao-Ming;
Chang, Yu;
Nan, Fei-Fei;
Yan, Jia-Qin;
Yu, Hui

Publication type:

Article

Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 506, doi. 10.1007/s10637-022-01218-6

By:

Wang, Lu;
Hu, Dan;
Xie, Bin;
Xie, Lin

Publication type:

Article

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 586, doi. 10.1007/s10637-022-01217-7

By:

Berlin, Jordan;
Tolcher, Anthony W.;
Ding, Cliff;
Whisenant, Jennifer G.;
Horak, Ivan D.;
Wood, Debra L.;
Nadler, Paul I.;
Hansen, Ulla Holm;
Lantto, Johan;
Skartved, Niels Jørgen Ø.;
Pedersen, Mikkel W.;
Patnaik, Amita

Publication type:

Article

Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 596, doi. 10.1007/s10637-022-01216-8

By:

Waqar, Saiama N.;
Robinson, Clifford;
Olszanski, Anthony J.;
Spira, Alexander;
Hackmaster, Melissa;
Lucas, Luisa;
Sponton, Laura;
Jin, Hulin;
Hering, Ursula;
Cronier, Damien;
Grinberg, Marianna;
Seithel-Keuth, Annick;
Diaz-Padilla, Ivan;
Berlin, Jordan

Publication type:

Article

Author Correction: Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion.

Published in:

2022

By:

Miao, Fa-an;
Chu, Kun;
Chen, Hai-rong;
Zhang, Meng;
Shi, Pei-cong;
Bai, Jin;
You, Yong-ping

Publication type:

Correction Notice

Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 634, doi. 10.1007/s10637-022-01214-w

By:

Kawachi, Hayato;
Tamiya, Motohiro;
Matsumoto, Kinnosuke;
Tamiya, Akihiro;
Yanase, Takafumi;
Tanizaki, Satoshi;
Kumagai, Toru

Publication type:

Article

Real-world data of off-label drug use in patients with actionable genomic alterations on next-generation sequencing.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 643, doi. 10.1007/s10637-022-01213-x

By:

Roman Souza, Gabriel;
Abdalla, Ahmed;
Arora, Sukeshi;
Mahadevan, Daruka

Publication type:

Article

Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 576, doi. 10.1007/s10637-022-01212-y

By:

Alves-Silva, Antônio Bruno;
Fenerich, Bruna Alves;
Fonseca, Natasha Peixoto;
Fernandes, Jaqueline Cristina;
Coelho-Silva, Juan Luiz;
Pereira-Martins, Diego Antonio;
Bianco, Thiago Mantello;
Scheucher, Priscila Santos;
Rego, Eduardo Magalhães;
Chahud, Fernando;
Machado-Neto, João Agostinho;
Figueiredo-Pontes, Lorena Lôbo;
Traina, Fabiola

Publication type:

Article

Biological evaluation of complexes of cyclopentadienyl M(CO)3+ (M = Re, 99mTc) with high blood–brain barrier penetration potential as brain cancer agents.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 497, doi. 10.1007/s10637-022-01211-z

By:

Mavroidi, B.;
Kaminari, A.;
Makrypidi, K.;
Shegani, A.;
Bouziotis, P.;
Pirmettis, I.;
Papadopoulos, M.;
Sagnou, M.;
Pelecanou, M.

Publication type:

Article

IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 487, doi. 10.1007/s10637-021-01210-6

By:

Lv, Xing;
Zhao, Qi;
Dong, Yanqun;
Yang, Lijun;
Gong, Jianhua;
Zheng, Yanbo;
Yang, Tao

Publication type:

Article

Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 519, doi. 10.1007/s10637-021-01209-z

By:

Topcu, Kubra Sena Bas;
Korucu, Emine Nedime;
Menevse, Esma;
Kocak, Nadir;
Duran, Tugce

Publication type:

Article

AM22, a novel synthetic microRNA, inhibits the proliferation of colorectal cancer cells by targeting core binding factor subunit β (CBFB).

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 469, doi. 10.1007/s10637-021-01208-0

By:

Meng, Fanyi;
Li, Jiawei;
Qiu, Yajing;
Zhang, Haiyang;
Zhang, Hongjian;
Wang, Weipeng

Publication type:

Article

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 478, doi. 10.1007/s10637-021-01207-1

By:

Jank, Bernhard J.;
Lenz, Teresa;
Haas, Markus;
Kadletz-Wanke, Lorenz;
Campion, Nicholas J.;
Schnoell, Julia;
Heiduschka, Gregor;
Macfelda, Karin

Publication type:

Article

The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients.

Published in:

Investigational New Drugs, 2022, v. 40, n. 3, p. 660, doi. 10.1007/s10637-021-01189-0

By:

Li, Chao;
Zhang, Mengdong;
Wang, Jianwen;
Zhang, Xiaodong

Publication type:

Article

Works in Investigational New Drugs, 2022, Vol 40, Issue 3

The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells.

Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma.

Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells.

Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancer.

Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.

The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis.

IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4.

An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer.

The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma.

A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects.

Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study.

Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells.

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors.

Author Correction: Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion.

Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study.

Real-world data of off-label drug use in patients with actionable genomic alterations on next-generation sequencing.

Phenformin increases early hematopoietic progenitors in the Jak2<sup>V617F</sup> murine model.

Biological evaluation of complexes of cyclopentadienyl M(CO)<sub>3</sub><sup>+</sup> (M = Re, <sup>99m</sup>Tc) with high blood–brain barrier penetration potential as brain cancer agents.

IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis.

Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer.

AM22, a novel synthetic microRNA, inhibits the proliferation of colorectal cancer cells by targeting core binding factor subunit β (CBFB).

Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro.

The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients.